 Deoxycytidine
"Deoxycytidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE.
| Descriptor ID |
D003841
|
| MeSH Number(s) |
D03.383.742.680.245.500 D13.570.230.329 D13.570.685.245.500
|
| Concept/Terms |
Deoxycytidine- Deoxycytidine
- Cytosine Deoxyribonucleoside
- Deoxyribonucleoside, Cytosine
- Cytosine Deoxyriboside
- Deoxyriboside, Cytosine
|
Below are MeSH descriptors whose meaning is more general than "Deoxycytidine".
Below are MeSH descriptors whose meaning is more specific than "Deoxycytidine".
This graph shows the total number of publications written about "Deoxycytidine" by people in this website by year, and whether "Deoxycytidine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 1 | 0 | 1 | | 1997 | 2 | 1 | 3 | | 1998 | 1 | 1 | 2 | | 1999 | 2 | 0 | 2 | | 2000 | 0 | 1 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 4 | 0 | 4 | | 2003 | 2 | 0 | 2 | | 2004 | 4 | 0 | 4 | | 2005 | 0 | 1 | 1 | | 2006 | 3 | 1 | 4 | | 2007 | 3 | 1 | 4 | | 2008 | 3 | 4 | 7 | | 2009 | 0 | 2 | 2 | | 2010 | 6 | 6 | 12 | | 2011 | 0 | 3 | 3 | | 2012 | 2 | 5 | 7 | | 2013 | 2 | 4 | 6 | | 2014 | 0 | 6 | 6 | | 2015 | 4 | 3 | 7 | | 2016 | 2 | 2 | 4 | | 2017 | 1 | 4 | 5 | | 2018 | 0 | 1 | 1 | | 2019 | 1 | 4 | 5 | | 2020 | 5 | 2 | 7 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Deoxycytidine" by people in Profiles.
-
Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, Small EJ, Morris MJ. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021 08 01; 39(22):2486-2496.
-
Ushida Y, Inoue Y, Ito H, Oba A, Mise Y, Ono Y, Sato T, Saiura A, Takahashi Y. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Pancreatology. 2021 Jan; 21(1):130-137.
-
Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.
-
Inoue Y, Saiura A, Oba A, Ono Y, Mise Y, Ito H, Sasaki T, Ozaka M, Sasahira N, Takahashi Y. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery. J Hepatobiliary Pancreat Sci. 2021 Feb; 28(2):143-155.
-
Dhar D, Raina K, Kumar D, Wempe MF, Bagby SM, Pitts TM, Orlicky DJ, Agarwal C, Messersmith WA, Agarwal R. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. Mol Carcinog. 2020 10; 59(10):1227-1240.
-
Dotan E, Cardin DB, Lenz HJ, Messersmith W, O'Neil B, Cohen SJ, Denlinger CS, Shahda S, Astsaturov I, Kapoun AM, Brachmann RK, Uttamsingh S, Stagg RJ, Weekes C. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Clin Cancer Res. 2020 10 15; 26(20):5348-5357.
-
Oesterheld JE, Reed DR, Setty BA, Isakoff MS, Thompson P, Yin H, Hayashi M, Loeb DM, Smith T, Makanji R, Fridley BL, Wagner LM. Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation. Pediatr Blood Cancer. 2020 07; 67(7):e28370.
-
Moreira DC, Venkataraman S, Subramanian A, Desisto J, Balakrishnan I, Prince E, Pierce A, Griesinger A, Green A, Eberhardt CG, Foreman NK, Vibhakar R. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine. J Neurooncol. 2020 May; 147(3):531-545.
-
van Roessel S, Strijker M, Steyerberg EW, Groen JV, Mieog JS, Groot VP, He J, De Pastena M, Marchegiani G, Bassi C, Suhool A, Jang JY, Busch OR, Halimi A, Zarantonello L, Groot Koerkamp B, Samra JS, Mittal A, Gill AJ, Bolm L, van Eijck CH, Abu Hilal M, Del Chiaro M, Keck T, Alseidi A, Wolfgang CL, Malleo G, Besselink MG. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Eur J Surg Oncol. 2020 05; 46(5):796-803.
-
Kamath SD, Kalyan A, Kircher S, Nimeiri H, Fought AJ, Benson A, Mulcahy M. Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. Oncologist. 2020 05; 25(5):e808-e815.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|